The use of anti-tuberculosis therapy for latent TB infection

Clicks: 213
ID: 6479
2010
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Star

Ranked #1,538 of 1,693 articles by views in Infection and drug resistance

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 1,693 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The use of anti-tuberculosis therapy for latent TB infection Justin T Denholm1,2, Emma S McBryde1,21Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, Victoria, Australia; 2Department of Medicine, (RMH/WH), University of Melbourne, Parkville, Victoria, AustraliaAbstract: Tuberculosis infection is of global public health significance, with millions of incident cases each year. Many cases, particularly in low-prevalence settings, result from the reactivation of latent tuberculosis infection (LTBI); potentially acquired years prior to active disease. Up to one-third of the world’s population has been infected with LTBI, and so may be at risk for future active TB disease. A variety of antituberculosis medications and treatment regimens have now been evaluated in the management of LTBI, with the aim of eradicating tuberculosis bacilli and reducing the likelihood of subsequent reactivation disease. This article reviews LTBI therapies and their use in clinical contexts, and considers future directions for individual and population-based strategies in LTBI management.Keywords: tuberculosis, latent tuberculosis, isoniazid, rifampicin, tuberculin skin test, interferon-gamma release assay
Reference Key
justin2010theinfection Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Justin T Denholm;Emma S McBryde and
Journal Infection and drug resistance
Year 2010
DOI
10.2147/IDR.S8994
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.